Research supported by the JKTG Foundation has been published in the journal Science Translational Medicine.
The research, Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin, includes work by Andrew Ewald, PhD, with Johns Hopkins University School of Medicine, a researcher with whom JKTG has worked on several projects.
The work highlighted in this most recent publication investigates the molecular mechanisms that cause metastasis in triple-negative breast cancer.
Learn more about Dr. Ewald’s work, as well as research from other leading breast cancer researchers, at the Foundation’s Oct. 27 symposium Moving Breast Cancer Treatments Forward. Additional details and registration can be found on the event site.
Featured news
Ted’s Take: It’s about the money
Money is what seems to drive things and money is what seems to drive organizations too. They all start with an overriding moral goal but after a while things often turn toward more money.
Ted’s Take: The best patient advocate? You.
When you’re a patient, you are kind of vulnerable. You have a problem, are often sketchy about what it is and the potential treatment or therapy needed. The bigger the problem, the more vulnerable you are. This makes you a perfect advocate.
Targeting effective treatments for triple-negative breast cancer
The JKTG Foundation recently awarded funding to Laura Heiser, Ph.D., Associate Professor and Vice Chair of Biomedical Engineering at the Oregon Health & Science University (OHSU) School of Medicine, to develop a prototype multiscale model designed to predict therapeutic responses of tumor ecosystems – a new frontier in breast cancer research.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133